摘要
目的:观察布林佐胺治疗青光眼患者的临床疗效以及安全性。方法:选取本院2011年2月-2012年4月期间收治的青光眼患者32例为研究对象,患者共计56只高眼压症以及术后残余青光眼、原发性的开角型青光眼,将其随机分为两组即治疗组和对照组,每组16例28只眼,治疗组采用布林佐胺(1%)治疗,对照组采用马来酸噻吗洛尔(0.5%)治疗,比较两药物降眼压的作用以及治疗过程中或者治疗后的不良反应。结果:两组患者在使用药物之后,眼压都有明显的下降,治疗前后比较差异均具有统计学意义(P<0.05);两组患者治疗后眼压下降的平均值比较差异无统计学意义(P>0.05);两组患者在治疗后血压变化和用药前比较差异无统计学意义(P>0.05);治疗组患者心率无明显变化,对照组患者出现了心率抑制,比较差异具有统计学意义(P<0.05),两组患者在治疗过程中均未发生严重的临床不良反应,无一例患者出现明显的全身性副作用。结论:布林佐胺治疗青光眼患者具有十分显著的降眼压作用,无心率抑制作用,是一种安全有效的治疗青光眼的理想药物,值得在临床上推广和应用。
Objective： To evaluate the clinical efficacy and safety of Bfinzolamide in treatment of glaucoma.Method： Glaucoma in 32 patients were treated from February 2011 to April 2012 in our hospital for the study, patients with a total of 56 OHT and postoperative residual glaucoma, primary open-angle glaucoma, were randomly dividedbrinzolamide （ 1% ） treatment for the two groups that the treatment group and the control group, 16 cases in each group of 28 eyes, the treatment group and the control group, treatment with timolol maleate （ 0.5% ）, comparing the two drugshypotensive effect as well as the course of treatment, or after treatment of adverse symptoms.Result： After the two groups of patients using the drug, the intraocular pressure have decreased significantly （ P〈O.05 ）, the difference was statistically significant; average IOP decreased after the treatment of the two groups of patients showed no significant difference （ P〉O.05 ） does not havestatistically significant; two groups of patients after treatment before the changes in blood pressure and medication was no significant difference （ P〉0.05 ） was not statistically significant; no significant changes in heart rate in patients of the treatment group, the control group in patients with heart rate suppression, the difference being statisticaUysignificance （ P〈0.05 ）, the two groups of patients did not occur during treatment of serious clinical adverse reactions, patients significant systemic side effects.Concluslon： Brinzolamide treatment of glaucoma patients clinically significant ocular hypotensive action, heart rate inhibition, is a safe and effective clinical ideal drug for the treatment of glaucoma, worthy of promotion and application of a wide range of clinical.
出处
《中国医学创新》
CAS
2013年第14期1-2,共2页
Medical Innovation of China
关键词
布林佐胺
青光眼
眼压
疗效
安全性
Brinzolamide
Glaucoma
Intraocular pressure
Efficacy
Security
